Bristol-Myers Squibb's innovative melanoma treatment Yervoy receives industry's highest honour

Bristol-Myers Squibb's innovative melanoma treatment Yervoy receives 
industry's highest honour 
Prix Galien Canada for innovation awarded to first treatment to show survival 
benefit for patients with the most deadly form of skin cancer 
MONTREAL, Nov. 21, 2013 /CNW/ - Bristol-Myers Squibb Canada is pleased to 
announce that YERVOY(®) (ipilimumab) a novel immuno-oncology therapy for 
metastatic melanoma has been awarded the Prix Galien Canada 2013 Innovative 
Product Award. This award, presented at a ceremony last night in Montreal, 
recognizes the significant impact Yervoy has had in treating this most 
aggressive and deadly form of skin cancer. 
Yervoy, which has now been approved in more than 40 countries around the 
world, was approved by Health Canada in February 2012 as the first and only 
treatment for advanced melanoma proven to extend survival in a phase three 
trial. Yervoy is indicated for the treatment of unresectable or metastatic 
melanoma in patients who have failed or do not tolerate other systemic therapy 
for advanced disease. 
"We are very proud of the difference Yervoy has made, and will continue to 
make, in the lives of Canadians with metastatic melanoma and their families," 
said Awny Farajallah, Vice-President, Medical, Bristol-Myers Squibb Canada. 
"Yervoy represents the important progress we have made in immuno-oncology, a 
rapidly-evolving field of cancer research and treatment focused on harnessing 
the power of the body's immune system to fight cancer." 
Unlike traditional therapies that target the tumour, immuno-oncology agents 
are designed to harness the natural capabilities of the patient's immune 
system to fight cancer by targeting the very same pathways tumor cells use to 
evade recognition and destruction. Yervoy specifically blocks cytotoxic T 
lymphocyte-associated antigen-4 (CTLA-4), which plays a role in suppressing 
the normal immune response. Yervoy blocks that suppression to allow the immune 
system to respond to melanoma cancer cells. 
Yervoy clinical evidence
In a pivotal randomized phase three clinical study, the median overall 
survival was 10 months for Yervoy and six months for the comparator treatment, 
a peptide vaccine (gp100). Yervoy has also demonstrated durable long-term 
survival in some patients. The Kaplan-Meier estimated survival rate with 
Yervoy at both one and two years was almost doubled when measured against 
patients treated with gp100, 46 per cent versus 25 per cent at one year and 24 
per cent versus 14 per cent at two years. Data were recently presented at the 
European Cancer Congress in Amsterdam in September on long-term survival 
results from a pooled analysis of 12 studies of Yervoy at different doses and 
regimens in more than 1,800 patients with metastatic or locally advanced or 
unresectable melanoma, which showed that approximately 22% of patients were 
alive at three years with some followed for up to 10 years. 
The types of adverse events (AEs) attributed to Yervoy are generally related 
to its mechanism of action, that is, immune-based. Immune-mediated adverse 
reactions, sometimes fatal, include enterocolitis, intestinal perforation, 
hepatitis, dermatitis, neuropathy, endocrinopathy as well as toxicity in other 
organ systems. Adverse events associated with Yervoy are managed by the 
administration of systemic corticosteroids, dose discontinuation and/or the 
use of other immuno-suppressants. 
About the Prix Galien Canada
The Prix Galien is the most prestigious award in the field of Canadian 
pharmaceutical research and innovation. Referred to as the Nobel Prize of 
pharmaceutical research, it recognizes the efforts and achievements of 
pharmaceutical research and development. The Prix Galien Canada is a branch of 
Innovation Life Canada. www.prix-galien-canada.com. 
About Bristol-Myers Squibb Canada
Bristol-Myers Squibb Canada is an indirect wholly-owned subsidiary of 
Bristol-Myers Squibb Company, a global biopharmaceutical company whose mission 
is to discover, develop and deliver innovative medicines that help patients 
prevail over serious diseases. For more information, please visit 
www.bmscanada.ca. 
YERVOY(® )is a registered trademark of Bristol-Myers Squibb Company.
 

SOURCE  Bristol-Myers Squibb Canada 
Monica Flores Senior Manager, Corporate and Business Communications 
Bristol-Myers Squibb Canada 514-333-3845 monica.flores@bms.com 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/November2013/21/c9501.html 
CO: Bristol-Myers Squibb Canada
ST: Quebec
NI: MTC ENT HEA  
-0- Nov/21/2013 10:59 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.